Clascoterone Hair Loss Results: Phase III Data Explained
Clinical trial results in hair loss are easy to misread, because the headline numbers depend entirely on the endpoint chosen and the size of the area measured. This article explains how clascoterone's results were generated and what they mean.
The endpoints that matter
The standard primary endpoint in androgenetic alopecia trials is change in target-area hair count: a 1 cm² region of the scalp is tattooed or marked, macro-photographed, and hairs are counted by a blinded assessor at baseline and at each visit.
Secondary endpoints typically include target-area hair width or total hair mass, investigator global assessment, and patient-reported satisfaction. Photographic global assessment is the one that best reflects what a person sees in the mirror.
Trial design and the vehicle arm
Clascoterone's alopecia studies were randomised and vehicle-controlled — participants received either the active solution or the identical carrier without clascoterone. This matters because the vehicle alone, plus the trial routine of daily scalp massage, produces a measurable response.
Any honest reading of results therefore focuses on the difference between active and vehicle, not the raw change from baseline in the active arm.
What was reported
The dose-ranging programme in men with androgenetic alopecia compared multiple clascoterone solution concentrations applied twice daily against vehicle over six months. It reported a dose-dependent improvement in target-area hair count, with higher concentrations separating most clearly from vehicle, and a tolerability profile dominated by mild local reactions.
That dose-dependence is the most scientifically persuasive part of the dataset: a graded response across concentrations is much harder to explain by chance or placebo than a single positive arm.
How to interpret the numbers responsibly
- A gain of a few hairs per cm² over vehicle is a genuine, meaningful clinical signal — it is not a cosmetic transformation.
- Six-month endpoints capture early cycle turnover; longer follow-up generally shows continued divergence.
- Trial adherence is near-perfect and real-world adherence is not; expect real outcomes to trail trial outcomes.
- Acne Phase III data establishes safety at scale; it does not establish hair efficacy. Keep the two datasets separate.
References
- Cassiopea clascoterone solution Phase II androgenetic alopecia dose-ranging results. — Clinical development disclosures
- Hebert A, et al. Topical Clascoterone Cream 1%: Two Phase 3 Randomized Clinical Trials. — JAMA Dermatology, 2020
- Target area hair count methodology in androgenetic alopecia trials. — PubMed — methodology literature
This library is educational. For the product itself — formulation, routine, pricing and shipping terms — return to the main website.
View the product